XML 28 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash Flows from Operating Activities    
Net income (loss) $ (10,028) $ (20,178)
Adjustments to reconcile net income (loss) to net cash from operating activities:    
Depreciation and amortization 17,649 12,080
Deferred income taxes (4,973) (5,196)
Non-cash asset impairment 2,864  
Non-cash equity-based compensation 14,303 9,054
Provision (recovery) for bad debt (1,833) 5
Gross profit from sales of lab tools (2,435)  
Change in contingent consideration (29,368)  
Excess tax benefits from equity-based compensation   (485)
Other, net   15
Changes in operating assets and liabilities:    
Accounts receivable (36,149) 25,095
Inventories 13,650 2,165
Prepaid expenses and other current assets (3,046) (4,801)
Accounts payable (9,679) 2,307
Accrued expenses, customer deposits, deferred revenue and other current liabilities 41,630 (15,235)
Income taxes payable 691 (821)
Other, net 124 605
Net cash provided by (used in) operating activities (6,600) 4,610
Cash Flows from Investing Activities    
Capital expenditures (10,476) (7,976)
Proceeds from the liquidation of short-term investments 216,050 422,903
Payments for purchases of short-term investments (157,733) (553,217)
Payments for purchase of cost method investment (2,388) (1,594)
Proceeds from sale of lab tools 7,034  
Other 126 25
Net cash provided by (used in) investing activities 52,613 (139,859)
Cash Flows from Financing Activities    
Proceeds from stock option exercises 9,485 313
Restricted stock tax withholdings (1,925) (2,358)
Excess tax benefits from equity-based compensation   485
Repayments of long-term debt (215) (199)
Net cash provided by (used in) financing activities 7,345 (1,759)
Effect of exchange rate changes on cash and cash equivalents (149) 117
Net increase (decrease) in cash and cash equivalents 53,209 (136,891)
Cash and cash equivalents as of beginning of period 210,799 384,557
Cash and cash equivalents as of end of period 264,008 247,666
Non-cash investing and financing activities    
Settlement of stock option exercise (shares withheld) $ 1,334